



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 38/26, C07K 14/605</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/47161 (43) International Publication Date: 23 September 1999 (23.09.99)</p>
<p>(21) International Application Number: PCT/US99/05571 (22) International Filing Date: 16 March 1999 (16.03.99) (30) Priority Data: 60/078,544 19 March 1998 (19.03.98) US (71) Applicant (for all designated States except US): BIONE- BRASKA, INC. [US/US]; 3820 N.W. 46th Street, Lincoln, NB 68524 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GOKE, Burkhard [DE/DE]; Mariborer Strasse 22, D-35037 Marburg (DE). BEGLINGER, Christoph [CH/CH]; Petersgraben 4, CH-4031 Basel (CH). COOLIDGE, Thomas, R. [US/US]; 181 Beebe Hill Road, Falls Village, CT 06031 (US). (74) Agent: SEASE, Edmund, J.; Zarley, McKee, Thomte, Voorhees & Sease, Suite 3200, 801 Grand Avenue, Des Moines, IA 50309-2721 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.</p>	
<p>(54) Title: HUMAN APPETITE CONTROL BY GLUCAGON-LIKE PEPTIDE RECEPTOR BINDING COMPOUNDS</p>		
<p>(57) Abstract A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.</p> <p style="text-align: center;">BEST AVAILABLE COPY</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE: HUMAN APPETITE CONTROL BY GLUCAGON-LIKE
PEPTIDE RECEPTOR BINDING COMPOUNDS

FIELD OF THE INVENTION

5 The present invention relates to the field of appetite control, and more particularly to compositions and methods where a glucagon-like peptide affects appetite suppression in humans, especially in humans with diabetes.

BACKGROUND OF THE INVENTION

10 The physiological mechanisms that produce satiety after food intake have not yet been defined. Several peptides normally secreted from the gastrointestinal tract during eating have been shown to suppress food intake if given before meals (Smith, G.P. and J. Gibbs. In: Martin JB, et al. eds. Neurosecretion and brain peptides. New York: Raven, 389-395 (1981); Gibbs
15 J. and Smith G.P. *Fed. Proc.* 45:1391-1395 (1986); Gibbs J. and Smith G.P. *Ann. N.Y. Acad. Sci.* 547:210-216 (1988)). During recent years, the role of the preabsorptive release of gut peptides (especially cholecystokinin, bombesin-like peptides and glucagon-like peptides) in the production of meal-ending satiety has been extensively investigated in animals (Gibbs J. and Smith G.P. (1988);
20 Gibbs J. et al. *J. Comp. Physiol. Psychol.* 84:488-495 (1973); Bado A. et al., *Pharmacol. Biochem. Behav.* 31:297-303 (1988); Weller A. et al., *Science*, 247:1589-1591 (1989); Silver A.J. et al., *Am. J. Physiol.*, 256:R646 R652 (1989); Turton M.D. et al., *Nature* 379:69-72, (1996)). Cholecystokinin (CCK) and bombesin-like peptides have also been studied in humans (Lieverse R.J. et al.,
25 *Gastroenterology* 106: 1451-1454 (1994); Gutzwiller J.P. et al., *Gastroenterology* 106: 1168-1173 (1994)). CCK, the first gut peptide proposed to act as a satiety signal (Gutzwiller, J.P. (1994)), has received the major share of interest in human studies reported in the literature.

30 Glucagon-like peptide-1 (7-36) amide (GLP-1), the biologically active form of the GLP-1 protein resulting from a post-translational modification of the prohormone proglucagon, is released from enteroendocrine cells from the

distal gut in response to food intake. GLP-1 has been shown to reduce food intake in rats when administered intracerebroventricularly, whereas intraperitoneal application of the peptide did not have any effect (Turton M.D. et al., *Nature* 379:69-72, (1996)). Further, when a GLP-1 receptor-specific antagonist was infused intracerebroventricularly, it blocked endogenous peptide, and thus affected only physiologically active circuits. Blocking endogenous GLP-1 causes healthy, already satiated animals to eat more. Turton and co-workers have, therefore, suggested that intracerebroventricular GLP-1 inhibits feeding in fasted rats (Turton, et al. (1996)). Others have reported no effect on appetite from the infusion of GLP-1 over 210 minutes in obese humans, thereby having discouraged further investigation of GLP-1 in human appetite suppression. These inconsistent studies have discouraged further investigation of GLP-1 for humans.

In animals, expression of GLP-1 receptors has been found in the hypothalamus, the brainstem and in the periventricular area, but not in the cortex. GLP-1 receptors were found in the endocrine pancreas (Hörsch, D. et al. *Pancreas* 14(3):290-294 (1997)), the adipose tissue (Valverde I. et al., *Endocrinology* 132:75-79 (1993)) and the stomach (Uttenthal, L.O. and Blazquez, E. *FEBS Lett*; 262:139-141 (1990); Schmidtler J. et al., *Am. J. Physiol.* 267:G423-G432 (1994)); and nerves containing GLP-1 have been identified in the brain (Jine S.L.C. et al., *J. Comp. Neurol.* 271:519-532 (1988); Salazar I. and Vaillant C. *Cell Tissue Res.* 261:355-358 (1990)). Thus, the GLP-1 receptor is present at sites where administration of exogenous GLP-1 appears to cause satiety; however, whether it is a satiety factor has not been confirmed. Injection of GLP-1 into the cerebral ventricles of fasted rats inhibited feeding, and this effect was blocked by the GLP-1 receptor antagonist exendin (9-39). Also, administration of exendin (9-39) alone doubled food intake in satiated rats (Turton M.D. et al., *Nature* 379:69-72, (1996)).

Even though GLP-1, as demonstrated here, controls appetite in normal humans, the use of GLP-1 to control appetite in diabetics is surprising for several reasons: first, diabetics normally have hyperinsulinemia, which is a

major appetite stimulant. Accordingly, there would be an expected major uncertainty whether GLP-1 could counteract this stimulation and deliver appetite control. Secondly, diabetics are characterized by having hyperglycemia, which in many causes a functional deterioration of the autonomous neural control systems for the GI tract, and in later stages causes structural damage to these systems. Accordingly, there would be an expected major uncertainty whether GLP-1 could have an appetite control function in such diabetics.

It is a primary objective of the present invention to suppress human appetite with GLP-1 or its biologically active analogues.

Another objective of the present invention is to combine GLP-1 or its biologically active analogues with a pharmaceutically acceptable carrier to provide an effective treatment composition for humans for use in appetite control, including in diabetics.

A yet further objective of the present invention is to provide a method, means and composition useful by humans to reduce the spontaneous urge for food intake without significant adverse side effect consequences to the person's metabolic balance.

The method and manner of accomplishing each of the above objectives, as well as others, will be apparent from the detailed description of the invention which follows.

SUMMARY OF THE INVENTION

A composition comprising a compound which binds to a receptor for glucagon-like peptide-1, said composition containing an amount of said compound effective to control appetite in a human in combination with a pharmaceutical carrier. Also provided is a method for controlling appetite in a human and for reducing spontaneous food intake by administering to the human a composition comprising a compound which binds to the receptor for glucagon-like peptide-1 and a pharmaceutical carrier, said composition

containing an amount of said compound effective to control appetite in a human. It is especially useful in humans with diabetes.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 is a graph of daily time course of procedures (see Example 1) carried out in a randomized, double-blind study with 16 healthy men aged $23.6 \pm .5$ years/ Dosage treatments of 0.375, 0.75 and 1.5 pmol/kg of GLP-1, separated by at least 7 days, were administered to the 16 subjects for 120 minutes with an intravenous infusion of 5% glucose used as a placebo control.

10 Figure 2 is a graph of subjective sensations of hunger (see Example 1) (upper panel 2A) and fullness (lower panel 2B) experienced by healthy male subjects before and after food intake during intravenous infusion of 5% glucose or one dose at various dose levels of human GLP-1.

15 Figure 3 is a graph of immunoreactive GLP-1 (IR-GLP-1) measured in the plasma (pmol/l) in response to graded doses of intravenous GLP-1 (see Example 1).

 Figure 4 is a graph of plasma CCK levels (pmol/l) (top panel 4A) and insulinogenic index (insulin/glucose) (lower panel 4B) in response to graded doses of GLP-1 (see Example 1).

20 Figure 5 is a graph of plasma leptin concentrations (ng/ml) in response to graded doses of intravenous GLP-1 (see Example 1).

 Figures 6(A) and (B) show appetite scores (hunger and fullness) for the twelve patients of Example 2.

25 Figures 7(A)-(D) show the plasma glucose, plasma glucagon, and plasma GLP-1 concentrations, as well as insulinogenic index for the 12 patients of Example 2.

30

DETAILED DESCRIPTION OF THE INVENTION AND ITS PREFERRED EMBODIMENTS

The inventors have discovered that the administration of graded doses of human GLP-1 produced plasma glucagon-like peptide-1 concentrations within physiological ranges and resulted in the reduction of intake of food in non-obese, healthy male subjects. Accordingly, the composition of the present invention is useful in therapeutic treatment for reducing food consumption.

The present invention provides a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 which is effective to control appetite and spontaneous food uptake in humans. In one embodiment, the receptor-binding compound is glucagon-like peptide-1. In another embodiment, the receptor-binding compound is a variant peptide in which the combination of the substitutions, deletions and variants does not differ by more than five amino acids from glucagon-like peptide-1. The receptor-binding compound can further comprise a polynucleotide, or an organic molecule having a molecular weight of not greater than about 5000.

The term glucagon-like peptide-1 includes glucagon-like peptide-1 related peptides and peptides which result from natural or synthetic enzymatic or chemical processing of glucagon-like peptide-1 related peptides. These peptides include peptides derived from enzymatic or chemical processing of GLP-1 (1-37), GLP-1 (7-37) and GLP-1 (7-36) amide. Preferably, the composition comprises a receptor-binding compound selected from the group consisting of a peptide which comprises the amino acid sequence of glucagon-like peptide-1 described above, or a variant peptide comprising an amino acid sequence that varies from the sequence thereof by one or more substitutions, deletions or insertions. In one embodiment, the receptor-binding compound is glucagon-like peptide-1. In another embodiment, the receptor-binding compound is a variant peptide in which the combination of the substitutions, deletions and variants does not differ by more than five amino acids from glucagon-like peptide-1. The receptor-binding compound can also be a polynucleotide or an organic molecule having a molecular weight of not greater

than about 5000. In this method, the composition preferably comprises a receptor-binding compound selected from the group consisting of a peptide comprising the amino acid sequence of glucagon-like peptide-1, which includes GLP-1 (7-37) and GLP-1 (7-36) amide, and a variant peptide comprising an amino acid sequence that varies from the sequence thereof by one or more substitutions, deletions or insertions. The preferred embodiments described for the composition are applicable to the method. In this aspect, the step of administering is preferably selected from the group consisting of a regimen of multiple subcutaneous injections, micropressure injection system, ambulatory pump, depot sustained-release injection, implant, deep lung sustained-release insufflation, skin patch, buccal patch or a sustained-release oral delivery dose form. Further, the step of administering preferably comprises providing graded dose regimen of doses in the range of from about 0.5 to about 2.0 pmol/kg per minute for intravenous delivery and to about 1-10 pmol/kg per minute for subcutaneous continuous delivery.

The inventors have demonstrated herein that short-term satiety effects can be induced by peripherally infused GLP-1. The results suggest that GLP-1 can act as an endogenous signal involved in the control of food intake in man.

The present composition can comprise glucagon-like peptides and related peptides and biologically active analogs of glucagon-like peptide-1 that bind to a glucagon-like peptide-1 receptor protein. The GLP-1 receptors are cell-surface proteins particularly including those present on insulin-producing beta cells. Glucagon-like peptides and analogs can include species that have insulinotropic activity and are agonists of, i.e., activate, the GLP-1 receptor molecule and its second messenger activity on *inter alia* insulin producing beta cells. Such agonists of glucagon-like peptide that exhibit activity through this receptor have been described: EP 0708179A2; Hjorth, S.A. et al., *J. Biol. Chem.* 269, (48):30121-30124 (1994); Siegel, E.G. et al. Amer. Diabetes Assoc. 57th Scientific Sessions, Boston (1997); Hareter, A. et al. Amer. Diabetes Assoc. 57th Scientific Sessions, Boston (1997); Adelhorst, K. et al. *J. Biol. Chem.* 269(9):6275-6278 (1994); Deacon, C.F. et al. 16th International

Diabetes Federation Congress Abstracts, *Diabetologia Supplement* (1997), Irwin, D.M. et al., *Proc. Natl. Acad. Sci. USA*. 94:7915-7920 (1997); Mosjov, S. *Int. J. Peptide Protein Res.* 40:333-343 (1992). Polynucleotides also include numerous species that are agonists of, i.e., activate, the GLP-1 receptor molecule and its second messenger activity on *inter alia* insulin producing beta cells, and include exendin-4 (see WO97/46584). GLP-1 mimetics that also are agonists of beta cells include, for example, enkephalin motif compounds. Glucagon-like peptide-1 antagonists are also known, for example see e.g. Watanabe, Y. et al., *J. Endocrinol.* 140(1):45-52 (1994), and include exendin (9-39) amine an exendin analog, which is a potent antagonist of GLP-1 receptors (see, e.g. WO97/46584).

Further embodiments include such proteins that are chemically synthesized, as well as any proteins or fragments thereof that are substantially homologous. "Substantially homologous", which can refer both to nucleic acid and amino acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between reference and subject sequences. For purposes of the present invention, sequences having greater than 90 percent homology, equivalent biological activity, and equivalent expression characteristics are considered substantially homologous. For purposes of determining homology, truncation of the mature sequence should be disregarded. Sequences having lesser degrees of homology, comparable bioactivity, and equivalent expression characteristics are considered equivalents.

It goes without saying that certain modifications to GLP-1 itself, or to the composition containing the same, may be made without departing from the spirit or scope of the present invention, and these are meant by the term biologically active analogues. Put another way, modifications both in the formula to provide some related analogues of GLP-1, and in the composition to provide either other forms of administration, or other pharmaceutically-

acceptable related compositions, may be made, as long as the desired human appetite control is achieved. These modifications are included in the scope of this invention.

Mammalian GLP peptides and glucagon are encoded by the same gene.

5 In the ileum the phenotype is processed into two major classes of GLP-peptide hormones, namely GLP-1 and GLP-2. There are four GLP-1 related peptides known which are processed from the phenotypic peptides. GLP-1 (1-37) has the sequence His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys

10 Gly Arg Gly (SEQ. ID NO:1). GLP-1 (1-37) is amidated by post translational processing to yield GLP-1 (1-36) NH₂, which has the sequence His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg (NH₂ (SEQ. ID NO:2); or is enzymatically processed to yield GLP-1 (7-37) which has the

15 sequence His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg Gly (SEQ. ID NO:3). GLP-1 (7-37) can also be amidated to yield GLP-1 (7-36) amide which has the sequence His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg (NH₂ (SEQ. ID

20 NO:4).

Intestinal L cells secrete GLP-1 (7-37) (SEQ. ID NO:3) and GLP-1 (7-36) NH₂ (SEQ. ID NO:4) in a ratio of 1 to 5 respectively. These truncated forms of GLP-1 *in situ* have short half-lives, i.e., less than 10 minutes, and are

25 inactivated by an aminodipeptidase IV to yield Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg Gly (SEQ. ID NO:5); and Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg (NH₂) (SEQ. ID NO:6), respectively. The peptides Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val

30 Lys Gly Arg Gly (SEQ. ID NO:5) and Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg

(NH₂) (SEQ. ID NO:6), have been speculated to affect hepatic glucose production, but do not stimulate the production or release of insulin from the pancreas.

There are six peptides in Hela monster venoms that are homologous to
5 GLP-1. Their sequences are compared to the sequence of GLP-1 in Table 1.

10

Insert Table 1 from page 9 of materials

15

a=GLP-1 (SEQ. ID NO:4)

b=Exendin 3(SEQ. ID NO:7)

20 c=Exendin 3(9-39)NH₂(SEQ. ID NO:8)

d=Exendin 4(SEQ. ID NO:9)

e=Helospectrin 1(SEQ. ID NO:10)

f=Helospectrin II(SEQ. ID NO:11)

g=Helodermin(SEQ. ID NO:12)

25 h=Q⁸, Q⁹ Helodermin(SEQ. ID NO:13)

The major homologies as indicated by the outlined areas in the Table are: peptides c and h are derived form b and g respectively. All 6 naturally occurring peptides (a, b, d, e, f and g) are homologous in positions 1, 7, 11 and
18. GLP-1 and exendins 3 and 4 (a, b and d) are further homologous in
30 positions 4, 5, 6, 8, 9, 15, 22, 23, 25, 26 and 29. In position 2, A, S and G are structurally similar. In position 3, residues D arid E (Asp and Glu) are

structurally similar. In positions 22 and 23 F (Phe) and I (Ile) are structurally similar to Y (Tyr) and L (Leu), respectively. Likewise, in position 26, L and I are structurally equivalent.

Thus, of the 30 residues of GLP-1, exendins 3 and 4 are identical in 15
5 positions and equivalent in 5 additional positions. The only positions where radical structural changes are evident are at residues 16, 17, 19, 21, 24, 27, 28 and 30. Exendins also have 9 extra residues at the carboxyl terminus.

The GLP-1 like proteins or peptides can be made by solid state direct amino acid synthesis. GLP-1 can also be made by conventional recombinant
10 techniques described in detail for example in Sambrook and Maniatis. "Recombinant", as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems.

The GLP-1 like proteins or peptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol
15 precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography (HPLC) can be employed for final purification steps.

20 The polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from prokaryotic or eukaryotic hosts (for example by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending on the host employed in a recombinant production procedure, the
25 polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

GLP-1 activity can be determined by standard methods, in general, by receptor-binding activity screening procedures involve providing appropriate
30 cells which express the receptor on the surface thereof, for example insulinoma cell lines such as RINmSF cells or INS-1 cells. See also Mosjov, S. (1992) and

EP0708170A2. In addition to measuring specific binding of tracer to membrane, cAMP activity or glucose dependent insulin production can also be measured. In one method, a polynucleotide encoding the receptor of the present invention is employed to transfect cells to thereby express the GLP-1 receptor protein. Thus, for example, such assay may be employed for screening for a receptor agonist by contacting such cells with compounds to be screened and determining whether such compounds generate a signal, i.e. activate the receptor.

Other screening techniques include the use of cells which express the GLP-1 protein receptor, for example, transfected CHO cells, in a system which measures extracellular pH or ionic changes caused by receptor activation. For example, potential agonists may be contacted with a cell which expresses the GLP-1 protein receptor and a second messenger response, e.g. signal transduction or ionic or pH changes, may be measured to determine whether the potential agonist is effective.

The glucagon-like peptide-1 receptor binding proteins of the present invention may be used in combination with a suitable pharmaceutical carrier for an appetite control therapeutic. Such compositions comprise a therapeutically effective appetite suppression control amount of the polypeptide, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes, but is not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, lactose, phosphate, mannitol, arginine, trehalose and combinations thereof. The formulations should be pharmaceutically elegant and suit the mode of administration. Although not limited to the following ranges and provided as an illustration, suggested dose ranges for various applications are 0.1 to 5.0 x 10⁻¹² mol/kg min for intravenous administration; 0.1 to 5.0 nmol/kg GLP-1 in any form as a single subcutaneous shot; continuous subcutaneous administration in a range from about 0.2 to 20 x 10⁻¹² mol/kg min. It is believed that the subcutaneous amounts may be up to or at least 10 times higher than those for intravenous application.

EXAMPLES

The following examples further illustrate an aspect of the present invention. However, it is in no way a limitation of the teachings or disclosure of the present invention as set forth herein.

5

(EXAMPLE 1 AND FIGURES 1-5)

The effect of graded intravenous doses of synthetic human GLP-1 on food intake in healthy male volunteers.

10 A randomized, double-blind design was carried out with 16 healthy men aged 23.6 ± 0.5 years. The weight of all subjects was within normal range considering their age, sex, and height. Each subject gave written informed consent for the study.

15 Four treatments (0, 0.375, 0.75 and 1.5 pmol/kg), separated by at least 7 days, were administered to the 16 subjects. The treatments were identical in design (Figure 1), except for the intravenous infusion of 5% glucose as placebo control or one dose of GLP-1. An identical standard meal was presented to the subjects on each occasion. The meal consisted of orange juice as an appetizer (480 kcal per l); ham sandwiches (60g bread, 10g butter, 25g ham 266 kcal per sandwich) and more orange juice and chocolate pudding (172 kcal per 100g);
20 coffee with cream and sugar (coffee could be sweetened if desired; therefore both cream and sugar were optional @ 12g cream=20 kcal, 4.5 sugar=18 kcal). No other food or liquid was allowed during the study. At the end of the study, the amount of food eaten and the amount of fluid ingested was measured by
25 absolute weight from which total caloric intake (food and fluid intake) was calculated.

Each subject was free to eat and drink as much as he wished, but the order of food intake had to follow the above schedule. To reduce participant's awareness of the amount of food being provided, food was served in excess.

30 On the first day of each treatment, each subject ate breakfast, if this was his normal custom; however, no snacks were allowed after 8:00 a.m. At

12:00 noon, an intravenous infusion of glucose 5%, or one dose of synthetic GLP-1 (7-36) amide at 0, 0.375, 0.75 and 1.5 pmol/kg per min, dissolved in 5% glucose solution was started in each subject and continued for the duration of each treatment. Infusions were delivered by ambulatory infusion pumps
5 through a teflon catheter inserted into a forearm vein. Participants were able to sit, eat, stand and walk comfortably while receiving infusions. At 60 minutes after the start of the respective infusion, the test meal was presented and each participant was invited to eat and drink as much as he liked.

Beginning at 12:00 noon, the subjects scored their subjective feelings of
10 hunger and fullness at 15 minute intervals throughout the treatments using a visual analogue scale of 0-10 and indicated the scores on a questionnaire. The scales and scores were designed as previously described (Welch I.M. et al. *Gut* 29:306-311 (1988); Welch I.M. et al. *Gastroenterology* 89:1293-1297 (1985); Drewe, J. et al. *Gastroenterology* 102:1654-1659 (1982)). For example, a score
15 of 0 for hunger indicated the subject was not hungry at all, 2 indicated slightly hungry, 5 indicated moderately hungry, 8 indicated very hungry, and 10 indicated absolutely ravenous.

The quantity of food eaten and volume of fluid drunk was measured. The time for each subject to complete his meal was also measured. From these
20 observations, the average rate of food and fluid intake, as well as the calorie intake, could be calculated. In the pre-meal period and after eating, blood was drawn at regular intervals into ethylenediaminetetraacetic acid (EDTA) tubes containing aprotinine (1000 KIU/ml blood) for glucose and hormone determinations.

25 The GLP-1 infusions were prepared from a freeze-dried synthetic powder, GLP-1 (7-36) amide purchased from Bachem (Bubendorf, Switzerland). The peptide was dissolved in 0.9% saline containing 0.5% human serum albumin, and prepared under aseptic conditions. Aliquots of 50µg/5ml were stored at -20°C. Infusion solutions were prepared by diluting
30 appropriate amounts of GLP-1 with 5% glucose containing 0.1% human serum albumin. Control solutions contained albumin in 5% glucose alone; and were

indistinguishable in appearance from GLP-1 infusions. Treatments were delivered in a double-blind fashion.

Glucose concentrations were measured by the hexokinase method. Plasma hormone concentrations of insulin, cholecystokinin, GLP-1 and leptin were measured as depicted in Figure 1. All hormone concentrations were determined by specific radioimmunoassay systems. For insulin and leptin concentrations commercially available test kits were used. Plasma immunoreactive CCK concentrations were measured by a sensitive radioimmunoassay based on the antiserum OAL656 which recognizes the sulfated tyrosine residue of CCK8, but has no relevant cross-reactivity with sulfated gastrin (<1%) and does not cross-react with unrelated gastrointestinal peptides (Hashimura, E. et al., *J. Immunol. Methods* 55:375-387 (1982)). GLP-1 was measured as previously described (Schirra, J. et al. *Proc. Assoc. Am. Phys.* 109(1):84-971 (1997)). The detection limit of the GLP-1 assay was 2 fmol/tube. The assay does not have any significant cross-reactivity with GIP, pancreatic glucagon, glicentin, oxyntomodulin or GLP-2. Intra-assay and inter-assay coefficients of variation were 3.4% and 10.4%, respectively.

The amount of food eaten and the amount of fluid drunk, the corresponding energy intake, and the duration of meal consumption were compared between the four by one-way analysis of variance (ANOVA) using the general linear model (GLM) procedure of the SAS software package (SAS Release 6.03. Cary, NC: SAS Institute, 1988). In the event of significant differences, ANOVA was followed by the Newman-Keuls multi-comparison test for pairwise comparisons (Sachs, L. *Angewandte Statistik*. Berlin, Springer, (1984)). The same statistical procedure was used to analyze the results of GLP-1 induced changes in plasma hormone concentrations using area under the curve (AUC) analysis. Scores for hunger and fullness were compared at the different time points before and after meals between the different treatments using multiple paired t-tests with Bonferroni correction (Sachs, L. *Angewandte Statistik*. Berlin, Springer, (1984)).

Intravenous infusion of graded doses of synthetic human GLP-1 dose-dependently reduced the amount of food eaten and the amount of fluid consumed ($p < 0.001$ and $p < 0.01$ respectively, Table 2). A maximal reduction of 35% in food consumption occurred with the highest dose of GLP-1 (1.5 pmol/kg per hour), resulting in a decrease in calorie intake of 32% ($p < 0.001$; Table 2).

Table 2 (Effect of graded doses of human GLP-1 on eating behaviour in 16 healthy male subjects)

Treatment	Control	GLP-1 0.375	GLP-1 0.75	GLP-1 1.5
		(pmol/kg/min)	(pmol/kg/min)	(pmol/kg/min)
Food quantity	587±36	531±35*	516±40*	384±34***
Calorie intake (keal)	1627±97	1520±95	1451±101*	1107±84***
Meal duration (min)	38±3	35±3	34±3*	30±3*
Fluid intake (ml)	708±57	748±52	689±48*	584±45**

10

(data are mean \pm 4 SEM).

$p < 0.05$ vs control

** $p < 0.01$ vs control

*** $p < 0.001$ vs control

15

Meal duration for subjects during GLP-1 infusions was also dose-dependently decreased compared to subjects infused with placebo and reached statistical significance at the highest dose ($p < 0.05$). None of the participants reported any abdominal discomfort or side effects during any infusions.

20

Furthermore, when questioned at the end of each experiment, none of the participants experienced or reported any adverse reactions.

The subjects experienced a reduced degree of hunger and a concomitant feeling of fullness in the pre-meal period with infusions of increasing doses of GLP-1. The difference reached statistical significance only for the highest dose of GLP-1 with respect to hunger and fullness feelings ($p < 0.05-0.01$, Figure 2).

5 No statistical differences were observed thereafter in hunger or fullness scores with any treatment after meal intake.

Graded doses of exogenous GLP-1 produced dose-dependent increases in plasma GLP-1 concentrations (Figure 3). The lower two doses produced plasma levels of 3.7 ± 0.6 pmol/l and 5.0 ± 0.6 pmol/l, respectively, which can
10 be considered physiological postprandial plasma levels, whereas the highest dose of GLP-1 resulted in supraphysiological plasma concentrations (Byrne, M.M. and Göke, B. *Diabetes*. Basel, Karger (13):219-233 (1997).

In the control experiment, glucose levels and insulin concentrations remained at pre-meal period levels. GLP-1 induced a dose-dependent, short-
15 lasting increase in blood glucose and plasma insulin concentrations. The results are depicted as an insulinogenic index in Figure 4. The insulinogenic index, calculated as the quotient insulin/glucose, more appropriately reflects insulin release (Schirra, J. et al. *Proc. Assoc. Am. Phys.* 109(1):84-9 (1997)) than changes of plasma glucose which invariably are associated with changes
20 in plasma insulin.

Plasma CCK concentrations did not change in the pre-meal period with any dose of GLP-1 (Figure 4). The results presented demonstrate that CCK is not released after graded doses of GLP-1 in the pre-meal period making it unlikely that CCK is the mediator of this response.

25 Finally, leptin levels did not change with any dose of GLP-1 administered, nor did leptin levels increase after meal intake (see Figure 5). Leptin, the product of the adipose-specific *ob* gene, regulates food intake and energy expenditure in animals (Campfield, L.A., et al. *Science* 269:546-549 (1995); Halaas, J.L. et al. *Science* 269:543-546 (1995); Pellymounter, M.A. et
30 al. *Science* 269:540-543 (1995)). An effect of leptin influencing short-term satiety has not yet been demonstrated in humans, but an action of

postprandial increase of GLP-1 stimulating adipose tissue to secrete leptin and suppress food intake is proposed. Leptin plasma concentrations did not change even during a pharmacological GLP-1 infusion (Figure 5) thus confirming results of Shalev et al. (Shalev, A. et al. *Metabolism* 46(7):723-725 (1997)).

5 The latter finding indicates that food intake suppression induced by GLP-1 is not mediated by leptin.

Graded GLP-1 infusions resulted in a dose-dependent reduction in food intake (maximal inhibition 35%; $p < 0.001$ vs control) and a similar reduction in calorie intake (32%; $p < 0.001$). Fluid ingestion was also reduced by GLP-1
10 (18% reduction, $p < 0.01$). There were no overt side effects produced by GLP-1, but subjects experienced less hunger and early fullness in the pre-meal period during GLP-1 infusion at the highest dose ($p < 0.05$).

These results demonstrate that intravenous infusions of GLP-1 decrease spontaneous food intake even at physiological plasma concentrations. The
15 date suggest an important role for GLP-1 in the regulation of the early satiety response in humans.

EXAMPLE 2

Twelve male patients were recruited for the study who had diabetes
20 mellitus type 2 for at least one year. Patients were admitted to a Research Unit after given written informed consent and after the experimental protocol had been explained to them. The mean age of the patients was 55 ± 2 years; their mean HbA_{1C} was 8.1 ± 4 and their mean BMi was 29.4 ± 1.2 . Seven
25 patients were on oral antidiabetics. The participants were tested on two different days in a placebo-controlled, randomized, double-blind, crossover study. The two test days were separated by at least one week and by no more than three weeks.

On each test day, patients arrived in the Research Unit in the morning, having fasted overnight. A standardized, fixed energy breakfast was then
30 served and it had to be completed before 8:30 a.m. After breakfast, patients were able to read and listen to music. At 11:00 a.m., two venflon catheters

were inserted into the antecubital veins of each arm, one for infusion, the other one for blood drawing. At 11:30 a.m. a fasting blood sample was taken and infusion was started (either GLP-1 at a dose of 1.5 pmol/kg per min or saline as placebo) and continued for the next two hours. Infusions were delivered by ambulatory infusion pumps. 60 min after the start of the respective infusion, a test meal was presented and the participants were invited to eat and drink as much as they liked.

Beginning with the infusions, participants scored their subjective feelings of hunger and fullness in 15 min intervals throughout the experiments using visual analogue scales (VAS) of 0-10 with text expressing the most positive and most negative rating anchored at each end. VAS were used to assess hunger, fullness, and prospective food consumption using scales and scores which have previously been designed.

Each subject was free to eat and drink as much as he wished until "comfortably satisfied" of a standard meal which consisted of a) orange juice as an appetizer (480 kcal/l); b) ham sandwiches (60 g, 10 g butter, 25 g ham: 266 kcal/sandwich) with more orange juice or with water; c) strawberry mousse (100 kcal/100 g); d) coffee with cream (coffee could be sweetened with aspartam if desired; both cream and aspartan were optional; 12 g cream=20 kcal). No additional food or fluid was allowed during the study. In addition, the order of food intake had to follow the above schedule. To reduce participants' awareness of the amount of food being provided, food was served in excess. The quantity of food eaten and the quantity of fluid drunk were measured. From these observations, the total energy intake could be calculated. In the pre-meal period and after eating, blood samples were taken in regular intervals for glucose and hormone determinations. Adverse events were assessed by the attending physician through close observation of each patient; in addition, each participant was questioned after each experiment and after he had completed the two tests whether he had experienced any adverse events.

For the GLP-1 infusions, commercially available synthetic human GLP-1 (7-36) amide was purchased from Bachem, Bubendorf, Switzerland. The peptide was dissolved in 0.9% saline solution containing 0.5% human serum albumin and prepared under aseptic conditions by the University of Basel Hospital Pharmacy. Aliquots of 50 µg/5 ml were stored at -20°C. Infusion solutions were prepared by diluting appropriate amounts of GLP-1 with 0.9% saline containing 0.1% human serum albumin. Control solutions contained albumin in 0.9% saline alone; they were indistinguishable in appearance from GLP-1 infusions. The solutions were prepared by a pharmacist who was not involved in the study. The physician in charge of the experiment was therefore not aware of the respective treatment, thereby making it possible to conduct treatments in a double-blind fashion.

Blood was drawn through the indwelling anticubital cannula into syringes on ice. These contained EDTA (6 µmol/l) and aprotinine (1000 KIU/l). After centrifugation, plasma hormone analyses were kept frozen at -20°C. Plasma glucose was analyzed by the glucose oxidase method. Insulin and glucagon concentrations in plasma were analyzed by commercially available radioimmunoassay kits (Biermann, Bad Nauheim, Germany). Immunoreactive GLP-1 was measured using the specific polyclonal antibody GA 1178 (Affinity Research, Nottingham, UK). Immunoreactivities were extracted from plasma samples on C-18 cartridges using acetonitrile for elution of samples. The detection limit of the assay was 0.25 pmol/l. Intra- and interassay coefficients of variation were 3.8% and 10.9%, respectively.

The amount of food eaten and the amount of fluid drunk as well as the corresponding energy intake were compared between the two treatments by Wilcoxon Signed Ranks Test using an SAS software package. The same statistical procedure was used to analyze the results of GLP-1-induced changes in plasma hormone concentrations using the Area Under the Curve (AUC) analysis. Scores for hunger and fullness were compared by calculating the S score from baseline (0 min) to 60 min of infusion using the Wilcoxon Signed Ranks Test. Differences were considered significant if p was <0.05.

Intravenous infusion of synthetic GLP-1 dramatically reduced the amount of food eaten and the amount of fluid consumption ($p=0.034$ and $p=0.011$, respectively; Table 3). The maximal reduction in food consumption with GLP-1 amounted to 29%, resulting in a decrease in calorie intake of 27% (5 $p=0.034$).

TABLE 3

(effect of GLP-1 (1.5 pmol/kg per min) on eating behaviour in 12 patients with diabetes mellitus type 2 compared with saline (control)). Data are mean \pm SEM.

Parameter	Saline	GLP-1
Food Quantity(g)	377 \pm 45	268 \pm 31*
Calorie intake (kcal)	944 \pm 99	694 \pm 79*
Fluid intake(ml)	441 \pm 58	360 \pm 60**

*) $p=0.034$

***) $p=0.011$

None of the participants reported any abdominal discomfort or side effects during any infusion of GLP-1. Furthermore, when questioned at the end of each experiment, none of them experienced or reported any adverse reaction.

The GLP-1 infusion significantly influenced the mean VAS (Figure 6). Subjects experienced a reduced degree of hunger and a concomitant increased feeling of fullness in the pre-meal period with GLP-1 infusion. When baseline scores were compared with the 60 min values, the difference reached statistical significance ($p=0.028$ for fullness and $p=0.026$ for hunger). Subjects felt less hungry and fuller with GLP-1 infusion compared with saline administration.

Figure 7 shows blood glucose, plasma insulin, and glucagon levels. Pre-study blood glucose concentrations were slightly hyperglycemic, but similar in both experiments. There was a continuous increase in blood glucose in response to meal intake in the control experiment. With GLP-1, blood glucose levels were significantly (AUC=1197 ± 101 mmol x min/L with saline vs 765 ± 65 with GLP-1; p<0.0001) lower for the duration of the experiment (Figure 7). Insulin concentrations were significantly (AUC=1775 ± 357 μU x min/L for saline vs 2920 ± 516 with GLP-1; p<0.0001) increased with GLP-1 compared to saline infusion, whereas the glucagon response was significantly reduced (p<0.006) with GLP-1. The GLP-1 infusion increased the plasma concentrations of GLP-1 (Figure 7).

Example 2 demonstrates that peripherally administered GLP-1 significantly reduces energy intake by inhibiting hunger sensations in patients with diabetes mellitus type 2. The marked effect on appetite is clearly illustrated by each of the food parameters, and accompanied with lower fasting as well as meal-stimulated plasma glucose concentrations. These data extend previous findings (Examples) in healthy volunteers that exogenous GLP-1 acts as a physiological regulator of food intake and appetite sensations.

It therefore can be seen that the present invention accomplishes all of its stated objectives.

What is claimed is:

1. A composition for appetite suppression comprising: an appetite suppression treatment effective amount of a compound which binds to a receptor for glucagon-like peptide-1, and a pharmaceutical carrier.
- 5 2. The composition of claim 1 wherein the receptor-binding compound is a peptide which comprises the amino acid sequence of glucagon-like peptide-1, or a biologically active analogue thereof.
- 10 3. The composition of claim 2 wherein the receptor-binding compound is glucagon-like peptide-1.
4. The compound of claim 2 wherein the receptor-binding compound is glucagon-like peptide-1 (7-37) which has the sequence His Ala Glu Gly Thr
15 Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Lcu Val Lys Gly Arg Gly (SEQ. ID NO:3).
5. The compound of claim 2 wherein the receptor-binding compound is glucagon-like peptide-1 (7-36) amide which has the sequence His Ala Glu Gly
20 Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg (NH₂) (SEQ. ID NO:4).
6. The composition of claim 2 wherein the receptor-binding compound is a biologically active analogue of GLP-1 in which the combination of the
25 substitutions, deletions and insertions in the amino acid sequence does not differ by more than five amino acids from the amino acid sequence of glucagon-like peptide-1.
7. The composition of claim 1 wherein the receptor-binding compound is a
30 polynucleotide.

8. The composition of claim 1 wherein the receptor-binding compound is an organic molecule having a molecular weight of not greater than about 5000.

9. A method for controlling appetite in a human by administering to the human a composition comprising: a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier, said composition containing an amount of said compound effective to control appetite in a human.

10. The method of claim 9 wherein the receptor-binding compound is a peptide which comprises the amino acid sequence of glucagon-like peptide-1, or a biologically active analogue thereof.

11. The method of claim 10 wherein the receptor-binding compound is glucagon-like peptide-1.

12. The method of claim 10 wherein the receptor-binding compound is glucagon-like peptide-1 (7-37) which has the sequence His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly (SEQ. ID NO:3).

13. The method of claim 10 wherein the receptor-binding compound is glucagon-like peptide-1 (7-36) amide which has the sequence His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg (NII₂) (SEQ. ID NO:4).

14. The method of claim 10 wherein the receptor-binding compound is a biologically active analogue of GLP-1 in which the combination of the substitutions, deletions and insertions in the amino acid sequence does not differ by more than five amino acids from the amino acid sequence of glucagon-like peptide-1.

15. The method of claim 9 wherein the receptor-binding compound is a polynucleotide.
- 5 16. The method of claim 9 wherein the receptor-binding compound is an organic molecule having a molecular weight of not greater than about 5000.
- 10 17. The method of claim 9 wherein the step of administering is in a manner selected from the group consisting of intravenous administration, single subcutaneous shot, continuous subcutaneous administration, a regimen of multiple subcutaneous injections, micropressure injection system, ambulatory pump, depot sustained-release injection, implant, deep lung sustained-release insufflation, skin patch, buccal patch and a sustained-release oral delivery dose form.
- 15 18. The method of claim 17 wherein intravenous administration is in a dose range of from about 0.1 to about 5.0×10^{12} mol/kg min.
- 20 19. The method of claim 17 wherein single subcutaneous shot administration is in a dose range of from about 0.1 to about 5.0 nmol/kg.
- 25 20. The method of claim 17 wherein continuous subcutaneous administration is in a dose range of from about 0.2 to about 20×10^{12} mol/kg min.
- 30 21. The method of claim 9 wherein the step of administering comprises providing graded dose regimen of doses in the range of from about 0.315 to about 2.0 pmol/kg per minute.
22. A method for reducing spontaneous food intake in a human by administering to the human a composition comprising: a compound which

binds to the receptor for glucagon-like peptide-1 and a pharmaceutical carrier, said composition containing an amount of said compound effective to reduce spontaneous food intake in a human.

5 23. The method of claim 22 wherein the receptor-binding compound is a peptide which comprises the amino acid sequence of glucagon-like peptide-1, or a biologically active analogue thereof.

10 24. The method of claim 23 wherein the receptor-binding compound is glucagon-like peptide-1.

25. The method of claim 23 wherein the receptor-binding compound is glucagon-like peptide-1 (7-37) which has the sequence His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He Ala
15 Trp Leu Val Lys Gly Arg Gly (SEQ. ID NO:3).

26. The method of claim 23 wherein the receptor-binding compound is glucagon-like peptide-1 (7-36) amide which has the sequence His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe He
20 Ala Trp Leu Val Lys Gly Arg (NH₂) (SEQ. ID NO:4).

27. The method of claim 23 wherein the receptor-binding compound is a biologically active analogue of GLP-1 in which the combination of the substitutions, deletions and insertions in the amino acid sequence does not
25 differ by more than five amino acids from the amino acid sequence of glucagon-like peptide-1.

28. The method of claim 22 wherein the receptor-binding compound is a polynucleotide.

30

29. The method of claim 22 wherein the receptor-binding compound is an organic molecule having a molecular weight of not greater than about 5000.

5 30. The method of claim 22 wherein the step of administering is in a manner selected from the group consisting of intravenous administration, single subcutaneous shot, continuous subcutaneous administration, a regimen of multiple subcutaneous injections, ambulatory pump, depot sustained-release injection, implant, deep lung sustained-release insufflation, skin patch, buccal patch and a sustained-release oral delivery dose form.

10

31. The method of claim 30 wherein intravenous administration is in a dose range of from about 0.1 to about 5.0×10^{-12} mol/kg min.

15

32. The method of claim 30 wherein single subcutaneous shot administration is in a dose range of from about 0.1 to about 5.0 nmol/kg.

33. The method of claim 30 wherein continuous subcutaneous administration is in a dose range of from about 1.0 to about 10×10^{-12} mol/kg min.

20

34. The method of claim 22 wherein the step of administering comprises providing graded dose regimen of doses in the range of from about 0.1 to about 20 pmol/kg per minute.




Fig. 1








Fig. 2A





- Placebo
- GPL-1 0.375 pmol/kg/min
- ▲ GPL-1 0.75 pmol/kg/min
- GPL-1 1.5 pmol/kg/min

Fig. 4A



- Placebo
- GPL-1 0.375 pmol/kg/min
- ▲ GPL-1 0.75 pmol/kg/min
- GPL-1 1.5 pmol/kg/min

Fig. 4B




Fig. 5




Fig. 6A




Fig. 6B




Fig. 7A




Fig. 7B




Fig. 7C




Fig. 7D

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/05571

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 38/26; C07K 14/605

US CL :514/12, 909; 530/308, 324

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12, 909; 530/308, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE, MEDLINE, BIOSIS, EMBASE, WPIDS

search terms: Glucagon like peptide 1 (GLP-1), appetite, satiety, receptor?, antiobesity or anti-obesity, human

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P ----- Y,P	MEERAN ET AL. Repeated Intracerebroventricular Administration of Glucagon-Like Peptide-1(7-36) Amide or Exendin-(9-39) Alters Body Weight in the Rat. Endocrinology. 1999, Vol. 140, No. 1, pages 244-250, especially pages 244 and 249.	1-8 ----- 9-34
X,P	NASLUND ET AL. Glucagon-Like Peptide-1 Increases the Period of Postprandial Satiety and Slows Gastric Emptying in Obese Men. Am. J. Clin. Nutr. 1998, Vol. 68, pages 525-530, especially pages 525 and 528.	1-34
X,P	GUTZWILLER ET AL. Glucagon-Like Peptide-1: A Potent Regulator of Food Intake in Humans. Gut. 1999, Vol. 44, pages 81-86, especially pages 81, and 84-85.	1-34

Further documents are listed in the continuation of Box C. See patent family annex.

<p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*B* earlier document published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p>	<p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>*A* document member of the same patent family</p>
--	---

Date of the actual completion of the international search 01 JUNE 1999	Date of mailing of the international search report 08 JUL 1999
--	--

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>D. Lawrence</i> ABDEL A. MOHAMED Telephone No. (703) 308-0196
---	--

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/05571

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 98/19698 A1 (ELI LILLY AND COMPANY) 14 May 1998, pages 4-18, 27-30, Example 1 and claims 1-15.	1-34
X,P ---- Y,P	FURUSE ET AL. Effects of Various N-terminal Fragments of Glucagon-Like Peptide-1(7-36) on Food Intake in the Neonatal Chick. Brain Research. 1998, Vol. 807, pages 214-217, see entire document.	1-8 ---- 9-34
X	WO 97/31943 A1 (NOVO NORDISK) 04 September 1997, pages 4-5, page 17, lines 24-31.	1-34
X - Y	TURTON ET AL. A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding. Nature. 04 January 1996, Vol. 379, pages 69-72, see entire document.	1-8 ---- 9-34
X - Y	NAVARRO ET AL. Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as Inhibitory Signal for Food and Water Intake. Journal of Neurochemistry, 1996, Vol. 67, No. 5, pages 1982-1991, especially pages 1982-1983 and 1988-1990.	1-8 ---- 9-34
X - Y	FURUSE ET AL. Intracerebroventricular Injection of Mammalian and Chicken Glucagon-Like Peptide-1 Inhibits Food Intake of the Neonatal Chick. Brain Research. 1997, Vol. 755, pages 167-169, see entire document.	1-8 ---- 9-34
A	US 5,120,712 A (HABENER) 09 June 1992, col. 2-6.	1-34
A	US 5,631,224 A (EFENDIC ET AL) 20 May 1997, col. 2, lines 65 to col. 4, lines 32.	1-34

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURRED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLOR OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.